Starpharma Holdings Limited
Starpharma Holdings Limited (SPL.AX) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Starpharma Holdings Limited (SPL.AX), covering cash flow, earnings, and balance sheets.
Starpharma Holdings Limited (SPL.AX) Income Statement & Financial Overview
Review Starpharma Holdings Limited SPL.AX income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $2.43M | $1.73M | $7.20M | $1.85M |
| Cost of Revenue | $4.68M | $5.22M | $770000.00 | $868000.00 |
| Gross Profit | -$2.26M | -$3.49M | $6.43M | $985000.00 |
| Gross Profit Ratio | -$0.93 | -$2.02 | $0.89 | $0.53 |
| R&D Expenses | $6.31M | $7.23M | $8.35M | $8.96M |
| SG&A Expenses | $3.13M | $3.64M | $3.03M | $3.48M |
| Operating Expenses | $9.45M | $10.87M | $11.38M | $12.45M |
| Total Costs & Expenses | $14.13M | $16.09M | $12.15M | $13.32M |
| Interest Income | $0.00 | $639000.00 | $828000.00 | $748000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $138000.00 | $546000.00 | $569000.00 | $580000.00 |
| EBITDA | -$5.25M | -$6.98M | -$3.56M | -$10.11M |
| EBITDA Ratio | -$2.16 | -$4.03 | -$0.49 | -$5.87 |
| Operating Income | -$11.71M | -$14.36M | -$4.95M | -$11.46M |
| Operating Income Ratio | -$4.82 | -$8.29 | -$0.69 | -$6.19 |
| Other Income/Expenses (Net) | $4.34M | $4.79M | $828000.00 | $779000.00 |
| Income Before Tax | -$7.37M | -$9.57M | -$4.13M | -$10.69M |
| Income Before Tax Ratio | -$3.04 | -$5.53 | -$0.57 | -$5.77 |
| Income Tax Expense | -$1.98M | -$2.44M | -$3.09M | -$3.33M |
| Net Income | -$5.39M | -$7.13M | -$1.03M | -$7.36M |
| Net Income Ratio | -$2.22 | -$4.12 | -$0.14 | -$3.97 |
| EPS | -$0.01 | -$0.02 | -$0.003 | -$0.02 |
| Diluted EPS | -$0.01 | -$0.02 | -$0.003 | -$0.02 |
| Weighted Avg Shares Outstanding | $414.80M | $407.98M | $410.86M | $409.54M |
| Weighted Avg Shares Outstanding (Diluted) | $416.20M | $412.37M | $410.86M | $409.54M |
The company's financials show resilient growth, with revenue advancing from $1.85M in Q4 2023 to $2.43M in Q2 2025. Gross profit remained healthy with margins at -93% in Q2 2025 compared to 53% in Q4 2023. Operating income hit -$11.71M last quarter, sustaining a consistent -482% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$5.25M. Net income rose to -$5.39M, while earnings per share reached -$0.01. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan